Market Overview

JP Morgan Reiterates Overweight, $33 PT on Centene Post Investor Day

Share:
Related CNC
Molina Healthcare's Issues Aren't Permanent, JPMorgan Says Amid Upgrade
Humana, Anthem Benefit From 'Attractive' Managed Care Sector, Jefferies Says
UnitedHealth's Q4 beat buoys peers (Seeking Alpha)

JP Morgan reiterates its Overweight rating and $33 price target on Centene (NYSE: CNC) as the company elaborates on visibility going forward.

JP Morgan notes, "Centene management laid out its view around medical cost issues across new TX/KY markets as well as the Celtic individual business. The good news here is that the company sees TX as driving more cost than KY in 2012 and also sees getting margins back in-line w/expectations by the 4th qtr in TX which should leave higher Q4 EPS run-rate into 2013. ...Look for focus going forward on KY commentary from competitors as well as TX rates post expiration of continuity of care regs on June 1."

CNC closed at $28.20 on Thursday.

Latest Ratings for CNC

DateFirmActionFromTo
Jan 2018Goldman SachsInitiates Coverage OnBuy
Nov 2017Credit SuisseInitiates Coverage OnNeutral
Oct 2017OppenheimerMaintainsOutperform

View More Analyst Ratings for CNC
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (CNC)

View Comments and Join the Discussion!